3SBio Inc (3SBio) is a fully integrated biotechnology company that carries out the research, development, manufacturing, and marketing of biopharmaceutical products. It develops products for the treatment of cancer, autoimmune diseases, nephrology, dermatology, and diabetes, among other diseases. The company operates through a single reporting segment, which is the development, production, marketing, and sale of biopharmaceutical products. The company’s product portfolio includes TPIAO, a recombinant human thrombopoietin (rhTPO) for the treatment of chemotherapy-induced thrombocytopenia (CIT) and immune thrombocytopenia (ITP); EPIAO, for the treatment of anemia associated with chronic kidney disease (CKD), the treatment of chemotherapy-induced anemia (CIA), and the reduction of allogeneic blood transfusion in surgery patients; Yisapu for the treatment of ankylosing spondylitis (AS) and psoriasis; Cipterbin (Inetetamab), for the treatment of HER2-positive metastatic breast cancer in combination with chemotherapy; Mandi, generically known as minoxidil tincture for the treatment of androgenetic alopecia (AGA) and alopecia areata and Remitch, nalfuraphine hydrochloride orally disintegrating tablets for the treatment of hemodialysis pruritus.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

3SBio has established a comprehensive R&D framework that emphasizes product quality as the core of its operations. The company operates four major R&D bases located in Shenyang, Shanghai, Shenzhen, and Hangzhou, which support a dual platform for biological and chemical drug development. This infrastructure covers the entire drug development process, from basic research and pre-clinical studies to clinical trials and new drug registration. The company has developed more than 30 listed products and 32 alternative products, with 22 recognized as National New Drugs, focusing on areas such as oncology, autoimmune diseases, nephrology, metabolism, and dermatology. Additionally, 3SBio Inc has applied for 285 invention patents, with 90 granted, and has undertaken over 40 state-level major projects. It specializes in developing biopharmaceutical products expressed in mammalian and bacterial cells, responsible for internal pre-clinical R&D. The company focuses on identifying promising chemical and pharmaceutical products and monoclonal antibody drugs, managing cooperative pre-clinical R&D. The company handles product registration with the NMPA and ensures compliance with Chinese regulations in pharmaceutical development, registration, and commercialization. The company operates 4 major R&D bases. It holds 285 invention patents applied, 90 granted. The company has a diverse pipeline covering nephrology, hematology, oncology, autoimmune diseases, ophthalmology, dermatology, and metabolism. The company collaborates with third-party companies and research institutions through its chemical platform. In FY2025, the company spent CNY1,520.3 in its R&D activities, which is 8.6% of its total revenue, and grew by 14.6% YoY.